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Summary: In order to produce antibodies for the radioimmunoassay of cholecystokinin the following animals
were immunized: 10 rabbits and 3 guinea pigs with cholecystokinin 1—33 coupled to bovine serum albumin, 9
rabbits and 2 guinea pigs with uncoupled cholecystokinin 1-33, 5 rabbits with cholecystokinin 10-20
coupled to bovine serum albumin and 4 rabbits with sulphated cholecystokinin 26-33 coupled to bovine
serum albumin. The titer, the binding energy and the specificity of the antibodies were evaluated. Cholecysto-
kinin 1—33, coupled to [125I]hydroxyphenylpropionic acid-succinimide ester (Bolton-Hunter reagent) to a
specific activity of 8.1-14.7 MBq/^g (219—398 Ci/ g) (n = 8), was used äs label. After the fourth immuni-
zation 5 rabbits immunized with albumin coupled cholecystokinin 1—33 had antibody titers between 1:22500
and 1:80000, while one rabbit immunized with uncoupled cholecystokinin 1-33 had a titer of 1:52000. The
affinity constant of these 6 antibodies ranged from K = 2.0 x 1010 to 72.3 x 1010 1/mol. One antibody was
specific for all sulphated forms of cholecystokinin, while the other 5 antibodies were specific for the large
molecular forms of cholecystokinin. In the guinea pigs immunized with cholecystokinin 1—33 and in the
rabbits immunized with cholecystokinin fragments antibody titers were less than 1:500. Concentrations of
cholecystokinin in an aqueous-acid extract of human and hog upper small intestine were 48.7 ± 6.7 pmol/g
and 46.2 ± 3.4 pmol/g, when measured with antibody T204 specific for sulphated forms of cholecystokinin,
and 49.7 ± 1.9 pmol/g and 39.2 ±1.6 pmol/g, when measured with antibody 1703 specific for large forms of
cholecystokinin. After ingestion of 60 ml corn oil in 6 normal subjects, plasma cholecystokinin increased from
2.7 ± 0.5 pmol/1 to 6.8 ±1.7 pmol/1 (p < 0.05) when measured with antibody T204, and from 1.0 ± 0.3
pmol/1 to 5.7 ±1.0 pmol/1 (p < 0.05) when measured with antibody 1703.
In conclusion, immunization of rabbits with cholecystokinin 1—33 resulted in high titer antibodies which
could be used in sensitive and specific radioimmunoassays for cholecystokinin.
Radioimmunassay für Cholecystokinin: Gewinnung und Bewertung von Antikörpern
Zusammenfassung: Zur Gewinnung, von Antikörpern für einen Radioimmunoassay für Cholecystokinin
wurden immunisiert: 10 Kaninchen und 3 Meerschweinchen mit an Rinderserumalbumin gekoppeltem
Cholecystokinin l "-33, 9 Kaninchen und 2 Meerschweinchen mit ungekoppeltem Cholecystokinin 1-33,
5 Kaninchen mit an Rinderseitimalbumin gekoppeltem Cholecystokinin 10-20 und 4 Kaninchen mit an Rin-
derserumalbumin gekoppeltem, sulfatiertem Cholecystokinin 26-33. Titer, Bindungsenergie und Spezifität
der Antikörper wurden bestimmt. Cholecystokinin 1—33, gekoppelt an [125I]Hydroxyphenylpropionsäure-
succinimid ester (Bolton-Hunter-Reagenz) mit einer spezifischen Aktivität von 8,1-14,7 MBq^g (219-398
, / ) (n = 8), wurde als Label benutzt. Nach der vierten Immunisierung hatten 5 der mit an Rinderserum-
albumin gekoppeltem Cholecystokinin 1-33 immunisierten Kaninchen Antikörpertiter zwischen 1:22500
und 1:80000, während ein mit ungekoppeltem Cholecystokinin 1—33 immunisiertes Kaninchen einen Titer
l) Supported by the Foundation for Medical Research FUNGO (grant No. 13-37-32).
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von 1:52000 aufwies. Die Affinitätskonstante dieser 6 Antikörper lag zwischen K = 2,0 x 1010 und 72,3 x
l O101/mol. Ein Antikörper war spezifisch für alle sulfatierten Cholecystokinine, während die anderen 5 Anti-
körper spezifisch für die großmolekularen Cholecystokinine waren. Bei den mit Cholecystokinin 1-33 immu-
nisierten Meerschweinchen und bei den mit Cholecystokinin-Fragmenten immunisierten Kaninchen waren
die Antikörpertiter kleiner als 1:500.
Die Cholecystokinin-Konzentrationen in einem wäßrig-sauren Extrakt aus Schleimhaut des oberen Dünn-
darms vom Menschen und vom Schwein betrugen 48,7 ± 6,7 pmol/g bzw. 46,2 ± 3,4 pmol/g, wenn sie mit
Antikörper T204 bestimmt wurden, der für die sulfatierten Cholecystokinine spezifisch ist. Wenn sie mit dem
für die großmolekularen Cholecystokinine spezifischen Antikörper 1703 gemessen wurden, lagen sie bei 49,7
±1,9 pmol/g bzw. 39,2 ±1,6 pmol/g. Nach Einnahme von 60 ml Maisöl stieg bei 6 gesunden Probanden die
Konzentration von Cholecystokinin im Plasma von 2,7 ± 0,5 pmol/1 auf 6,8 ±1,7 pmol/1 (p < 0.05; Messung
mit Antikörper T204), und von 1,0 ± 0,3 auf 5,7 ± 1,0 pmol/1 (p < 0.05; Messung mit Antiköripef 1703).
Wir folgern, daß die Immunisierung von Kaninchen mit Cholecystokinin 1-33 zur Bildung von hohen Anti-
körpertitern führt, die für empfindliche und spezifische Radioimmunoassays für Cholecystokinin benutzt
werden können.
Introduction . \
Cholecystokinin is one of the classical gut hormones
(1). This peptide hormone stimulates gall bladder
contraction and secretion of enzymes from the pan-
creas (2, 3). In extracts of gut and brain cholecysto-
kinin was found to be present in several molecular
forms (4). Originally cholecystokinin was isolated
from acid extracts of hog small intestine äs a basic
molecule containing 33 amino acid residues (chole^
cystokinin 1—33) with the chemical structure Lys-
Ala-Pro-Ser-Gly-Arg-Val-Ser-Met-Ile-Lys-Asn-
Leu-Gln-Ser-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-
Asp-Arg-Asp-Tyr(SO3)-Met-Gly-Trp-Met-Asp-
Phe (4, 5). A molecular form extended at the NH2-
terminus by 6 amino acid residues, Tyr-Ile-Gln-Gln-
Ala-Arg (cholecystokinin 1—39), was described
some years later (6). Recently, it was shown that in
neutral extracts of sheep brain a smaller molecular
form containing 8 amino acid residues (cholecysto-
kinin 26-33) predominates (4, 7).
Even though the first radioimmunoassay of chole-
cystokinin was reported äs early äs 1969 (8), only
few radioimmunoassays have so far been developed,
despite much effort. Several factors contribute to the
difficulties in developing a reliable radioimmunoas-
say for cholecystokinin:
1. difficulties in producing antibodies due to the low
immunogenicity (9),
2. an unacceptably high degree of cross-reactivity of
COOH-terminal antibodies with gastrin, because
both peptides share the same COOH-terminal
pentapeptide sequence,
3. suspected species differences in the NHi-terminal
sequence of cholecystokinin 1—33 resulting in
antibodies feacting with porcine cholecystokinin
but not with cholecystokinin from other species
(10, 11),
4. availability of only limited amounts of pure
cholecystokinin, and
5. difficulties in preparing immuno^reactive chole-
cystokinin labels. It has been shown that the con-
ventional oxidizing labelling methods, such äs the
chloramine T methöd and the lactoperoxidase
method, result in cholecystokinin labels of poor
immunoreactivity, probably düe to the delete-
rious effects of oxidation of the methionine re-
sidues in cholecystokinin (12). Recently, the la·?
belling problem has been overcome by using a
non-oxidizing labeÜing inethod. Using
[125I]hydroxyphenylpropionic aäd-$ucänimide
ester (Bolton-Hunter reagent) Rehfeld was able
to produce highiy immunoreactive cholecysto-
kinin 1—33 labels, and he suggested that chole-
cystokinin 1—33 was a good immunogen (12,
13).
In this report we present our experience with the
production of antibodies to cholecystokinin in rab-
bits and guineä pigs. Furthermore, the titer, the
binding energy and the specificity of the antibodies
were evaluated in radioimmunoassäys using Bolton-
Hunter labelled cholecystokinin 1-33. In addition,
we have measured cholecystokinin concenträtions in
extracts of human and hög üpper small intestine and
in human plasma after ingestion of fat, using ra-
dioimmunoassays employing an antibody specific for
sulphated forms of cholecystokinin and an antibody
specific for large forms of cholecystokinin.
J. Clin. Chem. Clin. Biochem. / Vol. 21, 1983 / No. 6
Jansen and Lamers: Radioimmunoassay of cholecystokinin 389
Materials and Methods
Peptides
99% pure porcine cholecystokinin 1-39 and 30% and 99% pure
porcine cholecystokinin 1—33 were obtained from Professor
Mutt, Karolinska Institute, Stockholm, Sweden; synthetic sulphat-
ed and unsulphated cholecystokinin 26-33 from the Squibb Insti-
tute, Princetown, N.J., USA; synthetic unsulphated human gastrin
1-17 from Imperial Chemical Industries, Cheshire, England; va-
soactive intestinal polypeptide from Peninsula Laboratories, San
Carlos, Ca, USA; gastric inhibitory polypeptide from Professor
Brown^ Vancouver, Canada; sulphated human gastrin 1 — 17 and
sulphated and unsulphated gastrin 1—34 from Professor Gross-
man, Los Angeles, Ca, USA; secretin synthesized by the Squibb
Institute, Princetown, N.J., USA, through the courtesy of Profes-
sor Grossman\ caerulein from Farmitalia, Milan, Italy; synthetic
cholecystokinin 10—20 from UCB, Br ssels, Belgium; porcine
pancreatic polypeptide, porcine glucagon and monocomponent
insulin from Novo Industry, Copenhagen, Denmark; synthetic
cholecystokinin 30-33 (tetragastrin) from Sigma, St. Louis, Mo,
USA.
Other reagents
[125I]hydroxyphenylpropionic acid-succinimide ester (Bolton-
Hunter reagent) was purchased from New England Nuclear, Bos-
ton, Ma, USA; Sephadex G 50 SF and SP-Sephadex C 25 from
Pharmacia, Uppsala, Sweden; l-ethyI-3-(3-dimethylaminoprop-
yl) carbodiimide hydrochloride from ICN, Plainview, NY, USA;
Freundes complete and incomplete adjuvant from Difco Laborato-
ries, Detroit, Mi, USA; Bordetella pertussis vaccine from RIV,
Bilthoven, The Netherlands; human and bovine serum albumin
from Behringwerke AG, Marburg/Lahn, West Germany; dextran
T 70 and bovine serum albumin (RIA-grade) from Sigma, St.
Louis, Mo, USA; trypsin TPCK from Worthington Biochemical
Corporation, Freehold, NJ, USA; sodium ethylmercurithiosalicy-
late from Aldrich-Europe, Beerse, Belgium; double antibody sol-
id phase from Organon, Oss, The Netherlands; all other reagents
from E. Merck, Darmstadt, FRG.
Animals
28 randomly bred rabbits and 5 randomly bred guinea pigs were
immunized.
Apparatus
Automatic γ-scintillation counter Philips PW 4800, Philips, Eind-
hoven, The Netherlands; digital diluter dispenser, Hamilton, Bo-
naduz, Switzerland.
Production of antibodies
Uncoupled cholecystokinin 1—33: 30% pure porcine cholecysto-
kinin 1-33 dissolved in 0.05 mol/1 sodium phosphate buffer pH
7.5 was used without modification.
Albumin^coupled peptides
30% pure porcine cholecystokinin 1-33, synthetic cholecystokin-
in 10-20, and synthetic sulphated cholecystokinin 26-33 were
dissolved in 0.05 mol/1 sodium phosphate buffer pH 7.5 and con-
jugated to bovine serum albumin by reacting with l-ethyl-3-(3-di-
methylaminopropyl) carbodiimide hydrochloride for 2 hours at
roorii temperature and a further 20 hours at 4 °C. The ratio be-
tween peptide, bovine serum albumin and l-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide hydrochloride on a molar base was
1:0.2:462. The antigen solution was emulsified with equal vo-
lumes of Freund?* adjuvant for the initial immunizations and with
equal volumes ot Freund*s incomplete adjuvant for booster injec-
tions. At the initial immunization 0.5 ml Bordetella pertussis vac-
cine was administered intramuscularly. Each rabbit was immun-
ized with 2 ml and each guinea pig with l ml of the emulsified
antigen. The initial injections were given intracutaneously on mul-
tiple sites into the back of the animals, while booster injections
were given subcutaneously with four weeks intervals on 4 sites.
The doses of antigen injected are given in table l. Seven days after
each booster injection blood was drawn from an ear vein in rabbits
and by cardiac puncture in guinea pigs.
Tab. 1. Type (BSA = bovine serum albumin coupled) and
amount of antigen used for production of antibodies to
cholecystokinin (CCK) in rabbits and guinea pigs.
Animal
species
Num- Antigen
ber
of
ani-
mals
Dose of
antigen
(nmol)
initial boost-
er
Rabbit 10 30%CCKl-33-BSA 20 10
Rabbit
Rabbit
Rabbit
Guinea pig
Guinea pig
9
5
4
3
2
30% CCK 1-33
CCK 10-20-BSA
sulphated CCK 26-33-BSA
30%CCKl-33-BSA
30% CCK 1-33
20
120
120
10
10
10
60
60
5
5
Radioiodina t ion
37 MBq (l mCi) [I25I]hydroxyphenylpropionic acid-succinimide
ester (Bolton-Hunter reagent) was dried under a gentle stream of
nitrogen according to the instructions of the manufacturer. Five
μg 99% pure cholecystokinin 1-33 dissolved in 5 μΐ 0.05 mol/1
acetic acid was added to the bottom of the vial. After addition of
15 μΐ 0.05 mol/1 sodium borate pH 10, the vial was gently agitated
for 30 minutes in an ice bath. To remove excess unreacted
[125I]hydroxyphenylpropionic acid-succinimide ester, 0.2 mol/1
glycine in 500 μΐ 0.05 mol/1 sodium borate pH 8.5 was added to
the mixture and the vial was agitated for 5 minutes. The reaction
mixture was chromatographed at 4 °C on a Sephadex G 50 SF
column, 100 x 0.9 cm, using 0.5 mol/1 acetic acid containing 2 g/l
gelatine s eluant. Every hour 5 fractions of l ml were collected.
The elution profile of the radioactivity is shown in figure l. Only
the second radioactive peak showed immunoreactivity. The frac-
tion with the highest radioactivity in peak II was diluted in the
eluting buffer and stored at —20 °C. This label retained its immu-
noreactivity for at least 3 months. Label damage was between 2
20 60 80 100
Fraction number
UO
Fig. 1. Elution profile of 125I radioactivity after application of
reaction mixture of cholecystokinin 1—33 with
[I25l]hydroxyphenylpropionic acid-succinimide ester
(Bolton-Hunter reagent) to a Sephadex G 50 SF column.
Peak II represents l belled cholecystokinin 1—33. Forde-
tails see text.
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and 7%, The specific activity of the label, deterrained according to
Stadil & Rehfeld (14), ranged from 8.1 to 14.7 ΜΒς/μ§ (219 to
398 nCi/[ig) (n = 8). When the label was rechromatographed on
SP-Sephadex C 25 using a 0.05 to 1.0 mol/l acetic acid gradient,
the radioactivity eluted s a single peak.
I n c u b a t i o n condit ions
Antibody titers were determined s follows. The assays were set
up in plastic tubes in an ice bath using 0.02 mol/l sodium barbital
buffer pH 8.4 containing 0.03 mmol/1 human serum albumin and
0.06 mmol/1 sodium ethylmercurithiosalicylate. The 2.2 ml incu-
bation volume consisted of 1.0 ml of approximately 2000 counts/
min label, 0.2 ml Standard solution, and 1.0 ml diluted antiserum.
The tubes were incubated for 96 hours at 4 °C To determine the
binding energy and cross-reactivity of the antibodies a pre-equili-
brium method was used. 0.2 ml Standard solution was incubated
with 0.1 ml diluted antiserum for 72 hours at 4 °C. After addition
of approximately 2000 counts/min Bolton-Hunter labelled chole1-
cystokinin 1-33 in 0.2 ml buffer, the mixture was incubated for
another 48 hours at 4 °C. All dilutions in this pre-equilibrium as-
say were made in 0.05 mol/l sodium phosphate buffer pH 7.4 con-
taining 0.08 mmol/1 human serum albumin and 0.06 mmol/1 sodi-
um ethylmercurithiosalicylate.
Separat ion procedure
Antibody-bound radioactivity was separated from free label by
addition of a 1.5 ml Suspension of 0.05 mol/l sodium phosphate
buffer pH 7.4 containing 25 mg activated charcoal, 2.5 mg dex-
tran T 70 and 16 mg bovine serum albumin. The tubes were vor-
texed and immediately centrifuged (3000 g for 10 minutes). In the
double-antibody Separation technique l ml of 1:20 diluted sheep
anti-rabbit immunoglobulin was added to the tube and incubated
for 4 to 8 hours at 4 °C before centrifugation. Both the supernat-
ant and the pellet were counted in an automatic γ-scintillation
counter.
Tryptic cleavage
230 μιηοΐ/ΐ 99% pure cholecystokinin 1^33 was incubated with 5
g/l trypsin for 60 minutes at 37 °C. The action of trypsin was ter-
minated by boiling for 10 minutes. The completeness of cleavage
of cholecystokinin 1-33 to the COOH-terminal octapeptide (sul-
phated cholecystokinin 26—33) was assessed by gel filtration of
cholecystokinin 1-33 before and after trypsinization on a Se-
phadex G 50 SF column, 200 x 1.5 cm, using 0.02 mol/l sodium
barbital buffer pH 8.4 s eluant at 4 °C. The eluate was measured
by radioimmunoassay using a COOH-terminal cholecystokinin
antibody and 125I labelled non-sulphated cholecystokinin 26-33
(15).
Tissue extract ion
Pieces of freshly obtained human (n = 3) and hog (n = 3) upper
small intestine were extracted in boiling water (l g/10 ml) for 10
minutes. After homogenization and centrifugation the supernat-
ant was decanted and the pellet was re-extracted in 0.5 mol/l acet-
ic acid (l g/10 ml) for 10 minutes. After centrifugation the super-
natant was added to the supernatant of the aqueous extraction,
rapidly frozen, lyophilized, dissolved in 0.05 mol/l sodium phos-
phate buffer and measured by radi immunoassay.
Measurement of cholecystokinin in plasm
Blood samples were collected in ice-chilled glass tubes containing
2 g/l ethylenediaminetetraacetate (EDTA). After centrifugation
the plasm was frozen at -20 °C. Cholecystokinin was extracted
from plasm by addition of 2 volumes of 960 ml/ί ethanol to l
volume of plasm . After mixing and centrifugation tHe supernat-
ant was evaporated to dryness under a stream f nitrogen at 37 °C.
The dried supernatant was reconstituted in assay buffer and 200
μΐ were incubated with 100 μΐ diluted antiserum for 72 hours at
4 °C. After addition of 200 μΐ labelled cholecystokinin 1-33 con-
taining approximately 2000 counts/min and incubation for anoth-
er 20 hours at 4 °C, free and antibody-bound peptide were separ-
ated and counted in a γ-scintillation counter. Cholecystokinin
1-33 was used s Standard, and antibodies 1703 and T204 s
antisera. 0.05 mol/l sodium phosphate buffeV pH 7.4 containing
0.08 mmol/1 human serum albumin and 0.06 mmol/ϊ sodium
ethylmercurithiosalicylate was used s assay buffer. Recovery of
cholecystokinin added to hormone-free plasm was 85.4 ± 2.0%
(mean ± SD; n = 11). Separation using plasma-coated charcoal
or the double-antibody solid phase technique gave identical re-
sults. The detectipn limit of the assays was between 0.5 and 1.0
pmol/1 plasm . Intra-assay Variation ranged from 4.6-8.4% and
inter^assay Variation from 11.3^15.4%.
Human studies
After an overnight fast 6 normal s bjects (4 males and 2 females;
mean age 30 years, r nge 23^38 years) ingested 60 rfil corn oil.
Blood samples were obtained at -5, 0, 5, 10, 15, 20, 30, 40, 50,
60, 75 and 90 minutes.
Statistics
Results were expressed s mean ± SEM, unless otherwise stated.
Studenfs t-test for paired data was used for analysis of the plasm
cholecystokinin results.
Results
The titers of the antibodies after the second, third
and fourth immunization are presented in table 2.
Antibodies with titers greater than 1:10000 were not
detected after the second immunization, while after
the third immunization 3 anijnals and after the
fourth immunization 6 animals had produced antibo-
dies with titers of more than 1:10000. Of the 10 rab-
bits immunized with albumin-coupled cholecysto-
kinin 1—33, 5 had antibody titers of more than
1:10000 ranging firorn 1:22500 to 1:80000. Of the 9
rabbits immunized with uncoupled cholecystokinin
1^33, one produced a high titer antibody, 1:100000
after the third arid 1:52000 after the fourth immuni-
zation. Immunization with synthetic cholecystokinin
fragments (cholecystokinin 10—20 and sulphated
cholecystokinin 26-33) did not fesult in antibodies
detectabie in radioimmunoassays employing Bolton-
Hunter labelled cholecystokinin 1-33. None of the
guinea pigs produced cholecystokinin antibodies
with titers of more than 1:500.
In radioimmunoassays using Bolton-H nter labelled
cholecystokinin 1-33 the binding eneijgy of 6 high
titer antibodies after the fourth immunization and of
one antibody after the third immunization (1703)
were determined. The affinity constants indicating
the binding energy between the antibodies and
cholecystokinin 1-33 (16) are presented in table 3.
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Four antibodies had very high affinity constants of
more than 5 x 10n 1/mol. These high binding ener-
gies were reflected in low ID5o's (Inhibition dose5o)
Tab. 2. The dilution of antibodies to cholecystokinin (CCK) in
the incubation mixture binding 50% of l fmol Bolton-
Hunter labelled cholecystokinin 1-33.
Animal number
Rabbit
30%CCKl-33-BSA
11
12
13
14
Tl
T2
T3 through T6
30% CCK 1-33
15
16
17
18
T7
T8 through TU
CCK10-20-BSA
1 through 5
Sulphated CCK 26-33-BSA
7 through 10
Reciprocal of antibody dilution
after
immuni- immuni- immuni-
zation II zation III zation IV
1000
5000
2000
2000
<500
n. t.
<500
<500
<500
2000
<500
<500
<500
<500
<500
1800
6000
10000
60000
<500
3700
<500
1700
2400
100000
1800
<500
<500
<500
<500
2750
27000
75000
50000
22500
80000
<500
<500
1500
52000
2500
2600
<500
<500
<500
Guinea pig
30% CCK 1-33-BSA
G l through G3 <500 <500 <500
30% CCK l-33
G4andG5 <500 <500 <500
n. t. = not tested
BSA = bovine sefum albumin coupled
between 2.8 and 5.0 pmol/1 in the radioimmunoas-
says. With these sensitive radioimmunoassays for
cholecystokinin 1-33, very low detection limits
ranging from 0.5 to 3 prnol/1 sample were obtained.
All antibodies cross-reacted with cholecystokinin
1-39 (table 3). Five antibodies (1204, 1304, 1404,
T104 and 1703/1704) did not cross-react with either
synthetic cholecystokinin fragments or cholecysto-
kinin fragments produced by trypsinization (table 3).
Furthennore, these antibodies did not show any
binding to sulphated or non-sulphated gastrins, to
COOH-terminal tetragastrin (cholecystokinin
30—33), to caerulein or to structurally unrelated
peptides such äs insulin, glucagon, pancreatic poly-
peptide, gastric inhibitory polypeptide, vasoactive
intestinal polypeptide or secretin. Antibody T 204
bound to cholecystokinin 33, cholecystokinin 39,
sulphated cholecystokinin 26—33, caerulein and to
trypsinized cholecystokinin 33 (table 3). Binding to
sulphated gastrin 1-17 and sulphated gastrin 1-34
was low, while binding to non-sulphated forms of
cholecystokinin or gastrin and to unrelated peptides
was absent. All 6 antibodies did not only bind to por-
cine cholecystokinin, but also to cholecystokinin in
human tissue extracts.
Standard curves for both types of antibodies are
shown in figures 2 and 3.
Concentrations of cholecystokinin in an aqueous
acid extract of human (n = 3) and hog (n = 3) upper
sinall intestine were 48.7 ± 6.7 pmol/g and 46.2 ±
3.4 pmol/g, when measured with antibody T204, and
49.7 ±1.9 pmol/g and 39.2 ±1.6 pmol/g, when
rneasured with antibody 1703.
Tab. 3. Binding energy, Inhibition dose 50 and cross-reactivity of high titer cholecystokinin (CCK) antibodies***.
Anti-
body
number
1204
1304
1404
T104
T204
1703
1704
K*
2.0
72.3
2.8
55.4
52.2
59.4
31.6
ID50**
26.0
4.5
24.0
5.0
3.3
2.8
5.1
CCK
1-33
1.0
1.0
1.0
1.0
1.0
1.0
1.0
CCK
1-39
0.80
0.49
0.80
0.50
1.12
0.89
0.88
CCK
10-20
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
Caerulein
<0.001
<0.001
<0.001
<0.001
0.20
<0.001
<0.001
Sul-
phated
CCK
26-33
<0.001
<0.001
<0.001
<0.001
0.93
<0.001
<0.001
Non-sul-
phated
CCK
26-33
<0.001
<0.001
<0.001
<0.001
<0.001
<0,001
<0.001
Trypsin-
ized
CCK
1-33
<0.001
<0.001
<0.001
<0.001
0.88
<0.001
<0.001
CCK
30-33
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
Sul-
phated
gastrin
1-17
<0.001
<0.001
<0.001
<0.001
0.016
<0.001
<0.001
Sul-
phated
gastrin
1-34
<0.001
<0.001
<0.001
<0.001
0.018
<0.001
<0.001
* Affinity constant K (X 1010 1/mol)
** Inhibition dose 50: dose of cholecystokinin l —33 which reduces binding between label and antibody by 50% (pmol/1)
*** None of the antibodies showed cross-reactivity with non-sulphated gastrin 17, non-sulphated gastrin 34 or unrelated regulatory pep-
tides
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Fig. 2. Standard curves of antibody 1703 using Bolton-Hunter la-
belled cholecystokinin 1-33. The antibody binds to
cholecystokinin 1—33 (O) and cholecystokinin 1—39 ( ),
but not to sulphated gastrin (A), unsulphated gastrin (V),
sulphated cholecystokinin 26-33 (x), unsulphated chole-
cystokinin 26—33 (O), trypsinized cholecystokinin 1-33
( ) or caerulein (D).
60 ml Corn oil
orally
-5 0 5 10" 1520 "30 40 "SO
t [min)
60 75
Fig. 4- The effect of ingestion of 60 ml corn oil on plasma chole-
cystokinin cohcentrations in 6 normal subjects. Open cir-
cles indicate antibody T?04 and filled circles antibody
1703. Asterisks indicate significant differences from basal
value (p < 0.05).
5 10 50 100
c[pmol/l]
500 1000
Fig. 3. Standard curves of antibody T204 using Bolton-Hunter la-
belled cholecystokinin 1-33. The antibody binds to
cholecystokinin-gastrin peptides containing the sulphated
tyrosine region: cholecystokinin 1—39 ( ), cholecystokin-
in 1-33 (O), trypsinized cholecystokinin 1-33 (d), sul·
phated cholecystokinin 26-33 (x), caerulein (D) and sul-
phated gastrin (A). Binding to cholecystokinin-gastrin
peptides lacking the sulphated tyrosine region is absent:
unsulphated cholecystokinin 26—33 (O), and unsulphated
gastrin (V).
Basal plasma cholecystokinin concentrations were
very low, 2.7 ± 0.5 pmol/1 äs measured with anti-
body T204, and 1.0 ± 0.3 pmol/1 äs measured with
antibody 1703. Ingestion of corn oil induced signifi-
cant increases in plasma cholecystokinin (p < 0.05).
The peak plasma cholecystokinin concentrations
were found 20 minutes after ingestion of the corn oil.
The increases in plasma cholecystokinin were similar
for both antibodies (fig. 4).
Discussion
This study shows that cholecystokinin 1^-33 is an ex-
cellent immunogen when Bolton-Hunter labelled
cholecystokinin l—33 is employed äs the rädioactive
peptide in radioimmunoassays. immunization of
rabbits with albumin-coupled cholecystokinin 1^33
produced high titer antibodies in 5 of 10 animals,
while immunization of 9 rabbits with üricoüpled
cholecystokinin 1—33 produced high titer antibodies
in one animal. Four of these antibodies had high
binding energies with affinity constants of more than
5 x 1011 1/mol. No antibodies Were obtained in gui^
nea pigs immunized with uncoupled or albumin-
coupled cholecystokinin 1-33 or in rabbits immun-
ized with albumin-coupled cholecystokinin frag-
ments. Therefore, immunization of rabbits with al-
bumin-coupled cholecystokinin 1—33 seems to be
the most suitable method to prodüce antibodies for
the radioimmunöassäy of cholecystokinin. In con-
trast to a previous report (9), our results confirm
Rehfeld's finding that cholecystokinin 1-33 has
good immunogenic properties (12). It has been
claimed by Rehfeld that cholecystokinin 1—33 is a
good immunogen provided cholecystokinin is not ex-
posed to oxidation during the labelling procedure
(12). However, high titer cholecystokinin antibodies
have been described in radioimmunoassays using
cholecystokinin 1—39 or nonsulphated cholecysto-
kinin 26-33 iabelled with n*I by the chloramine T
method (15, 17, 18). On the other hand, it seems to
be extremely difficult to raise high titer antibodies
against cholecystokinin 1—33 when an oxidizing la-
belling method is used. Thompsotfs group has pro-
duced an antibody against cholecystokinin 1-33
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which binds 25 to 35% of cholecystokinin 1—39, la-
belled with 125I by the chloramine T method, at a
final dilution of 1:100000 (17). In most radioimmu-
noassays using cholecystokinin 1—33 or cholecysto-
kinin 1-39, labelled by the chloramine T method,
the titers of the antibodies are extremely low (8, 10,
19, 20, 21). From the present study it carmot be con-
cluded whether the excellent immunogenicity of
cholecystokinin 1—33 in our hands is attributable to
the immunization schedule employed or to the use of
a non-oxidizing labelling method. Using Bolton-
Hunter labelled cholecystokinin 1—33, Rehfeld re-
ported cholecystokinin antibodies with a titer be-
tween 1:10000 and 1:30000 in 3 of 10 rabbits im-
munized with albumin-coupled cholecystokinin
1-33 (12). However, none of these antibodies had
affinity constants above 5 x 10U 1/mol. Byrnes et al.
(22) immunized 16 rabbits with albumin-coupled
cholecystokinin 1—33 and only one of the animals
produced an antibody with a titer of 1:10000. When
Bolton-Hunter labelled cholecystokinin 1—33 was
used in the assay the affinity constant was 5.5 x l O11
1/mol (22). Rehfeld suggested that cholecystokinin
1—33 is particularly immunogenic in guinea pigs
(12). Twelve of 30 animals produced antibodies with
titers between 1:10000 and 1:50000. Three of these
antibodies had affinity constants of iriore than 5 x
10111/mol. While Rehfeld (12) and Byrnes et al. (22)
did not find antibody titers higher than 50000, we
found this level of titers in 4 rabbits. Some authors
advocate an immunization schedule in which crude
cholecystokinin 1—33 is used for the initial immuni-
zations followed by 99% pure cholecystokinin 1—33
for the final immunization (17). In our study excel-
lent antibodies were obtained after immunization
with 30% pure cholecystokinin 1-33. 99% pure
cholecystokinin 1-^33 is difficult to obtain and our
data do not support the need for highly purified
cholecystokinin 1—33 äs immunogen.
The high binding enefgy of 4 antibodies (K > 5 x
l O11 1/mol) in the present study was reflected in the
high sensitivity of the radioimmunoassays. The dose
of cholecystokinin 1—33 at which the binding be-
tween label and antibody was inhibited by 50%
(iD50) ranged from 2.8 to 5.0 pmol/1. The detection
limit of these assays was between 0.5 and 3 pmol/1
sample. These assays were extremely sensitive and
they were able to measure the very low concentra-
tions of cholecystokinin present in the circulation
(fig. 4).
Five antibodies bound to cholecystokinin 1-33 and
cholecystokinin 1—39, but not to synthetic cholecys-
tokinin fragments (sulphated and non-sulphated
cholecystokinin 26—33, cholecystokinin 30—33,
cholecystokinin 10-20) or cholecystokinin frag-
ments prepared by trypsinization of cholecystokinin
1-33 (cholecystokinin 1-6, cholecystokinin 7-11,
cholecystokinin 12-21, cholecystokinin 22-25, sul-
phated cholecystokinin 26-33). Go et al. (10) and
Straus & Yalow (11) produced antibodies to chole-
cystokinin 1—33 which reacted only with porcine
cholecystokinin, but not with cholecystokinin from
other species. They suggested that there might be
species differences in the structure of cholecystokin-
in 1—33 at the NHb-terminus. Our antibodies not
only bound to porcine cholecystokinin but also to
human cholecystokinin. Since the antibodies do not
cross-react with gastrin or with structurally unrelated
peptides, these antibodies are extremely suitable for
quantifying large forms of cholecystokinin in blood
and tissue. One antibody (T204) seems to be direct-
ed to the sulphated tyrosine region of the molecule.
It binds to large cholecystokinin and cholecystokinin
fragments containing the sulphated tyrosine region
(cholecystokinin 1—39, cholecystokinin 1—33, cae-
rulein, sulphated cholecystokinin 26—33, trypsinized
cholecystokinin 33) but not to unsulphated cholecys-
tokinin fragments (non-sulphated cholecystokinin
26—33, cholecystokinin 10—20, cholecystokinin
30-33). Since the binding to sulphated gastrin 1-17
and sulphated gastrin l—34 is low and the binding to
non-sulphated gastrin 1 — 17 and gastrin 1—34 and
structurally unrelated peptides is absent, this anti-
body is suitable for quantifying the sulphated forms
of cholecystokinin in blood and tissue. Since only
sulphated molecular forms of cholecystokinin pos-
sess biological activity, this assay will quantify only
the biological active forms of cholecystokinin.
In conclusion, immunization of rabbits with chole-
cystokinin 1—33 resulted in antibodies which can be
used in sensitive and specific radioimmunoassays for
cholecystokinin.
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